Copenhagen, 2015-05-13 14:41 CEST (GLOBE NEWSWIRE) -- 13 May 2015 - Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) (“Zealand”) will announce its interim report for Q1 2015 on the morning of Friday, 22 May 2015 in accordance with the company’s financial calendar.
Conference call – Friday, 22 May at 14.00 CET/ 08.00 EDT
On the day of release, Zealand’s management will host a conference call at 14.00 CET/ 08:00 EDT to present its Q1 results for 2015. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, Chief Financial Officer, and Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications. The presentation will be conducted in English and followed by a Q&A session.
The dial-in numbers are:
DK standard access +45 32 71 16 58
UK and international +44 (0) 20 3427 1916
US (free dial-in) +1 877 280 1254
A live audio cast of the call with an accompanying slide presentation will be available via the following link, http://edge.media-server.com/m/p/yffy2yk6 , accessible also from the Investor section of the company’s website (www.zealandpharma.com). Participants are advised to register for the audio cast approximately 10 minutes before the start.
A replay of the event will be made available from the Investor section of Zealand’s website following the call.
●●●●●
For further information, please contact:
Hanne Leth Hillman, Senior Vice President for Investor Relations and Communications
Tel: +45 50 60 36 89, email: hlh@zealandpharma.com
About Zealand Pharma
Zealand Pharma A/S (“Zealand”) (Nasdaq Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand has leading expertise in the discovery, design and development of novel peptide medicines and possesses in-house competences in clinical trial design and management with a therapeutic focus on metabolic diseases and acute care indications. The company is advancing a pipeline of novel wholly-owned medicines alongside a partnered product and development portfolio.
Zealand’s first invented medicine, lixisenatide, a once-daily prandial GLP-1 agonist for the treatment of Type 2 diabetes, is marketed globally (ex-US) as Lyxumia® and in Phase III development as a single-injection combination with Lantus® (LixiLan), both under a global license agreement with Sanofi. US regulatory submission of Lyxumia® is planned for Q3 2015 and US/EU regulatory submissions for LixiLan in Q4 2015 and Q1 2016, respectively.
Zealand’s wholly-owned products include danegaptide (prevention of Ischemic Reperfusion Injury) in Phase II and the stable glucagon product, ZP4207 (treatment of severe hypoglycemia) in Phase I as well as several preclinical peptide therapeutics. Partnering represents an important component of strategy to leverage in-house expertise, share development risk in large clinical trials, provide funding and commercialize the company’s products. Zealand currently has global license agreements and partnerships with Sanofi, Helsinn Healthcare, Boehringer Ingelheim and Eli Lilly.
For further information: www.zealandpharma.com Follow us on Twitter @ZealandPharma
